Background Antipsychotic treatment is associated with metabolic disturbance. However, the
degree to which metabolic alterations occur in treatment with different antipsychotics is …

People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …

People with psychotic disorders show abnormalities in several organ systems in addition to
the central nervous system (CNS); and this contributes to excess mortality. However, it is …

Immune parameters are elevated in psychosis, but it is unclear whether alterations are
homogenous across patients or heterogeneity exists, consistent with the hypothesis that …

BackgroundIt is unclear what the prevalence of metabolic syndrome (MetS) in drug-naïve
first-episode of psychosis (FEP) is, as previous meta-analyses were conducted in minimally …

Importance No clinically applicable diagnostic test exists for severe mental disorders. Lipids
harbor potential as disease markers. Objective To define a reproducible profile of lipid …

Background Insulin resistance predisposes to cardiometabolic disorders, which are
commonly comorbid with schizophrenia and are key contributors to the significant excess …

The outcome of first-episode psychosis (FEP) is highly variable, ranging from early
sustained recovery to antipsychotic treatment resistance from the onset of illness. For …